Skip to content

Based on my review of the GO-CAM model and relevant resources, I'll now provide a comprehensive assessment of the model "TREM2 activated by APOA1. (Human)" (gomodel:6606056e00001462).

Review of GO-CAM Model 6606056e00001462

Model Overview

The model gomodel:6606056e00001462 entitled "TREM2 activated by APOA1. (Human)" represents a signaling pathway in which APOA1 (Apolipoprotein A-I) activates TREM2 (Triggering receptor expressed on myeloid cells 2), which then triggers a signaling cascade involving TYROBP/DAP12 (TYRO protein tyrosine kinase-binding protein) and leading to SYK (Spleen tyrosine kinase) activation.

Model Structure and Biological Content

The model contains four connected molecular activities that form a clear signaling pathway:

  1. APOA1 (UniProtKB:P02647) performs receptor ligand activity (GO:0048018) in the extracellular space (GO:0005615), which is part of the cellular response to lipoprotein particle stimulus (GO:0071402)

  2. TREM2 (UniProtKB:Q9NZC2) performs transmembrane signaling receptor activity (GO:0004888) at the plasma membrane (GO:0005886), also part of the cellular response to lipoprotein particle stimulus (GO:0071402)

  3. TYROBP/DAP12 (UniProtKB:O43914) performs protein-macromolecule adaptor activity (GO:0030674) at the plasma membrane (GO:0005886), as part of the cellular response to amyloid-beta (GO:1904646)

  4. SYK (UniProtKB:P43405) performs protein tyrosine kinase activity (GO:0004713) in the cytoplasm (GO:0005737), also as part of the cellular response to amyloid-beta (GO:1904646)

The causal connections in the model use appropriate relationship predicates: - APOA1 directly positively regulates (RO:0002629) TREM2 - TREM2 directly positively regulates (RO:0002629) TYROBP - TYROBP directly positively regulates (RO:0002629) SYK

Strengths of the Model

  1. The model correctly represents the TREM2-TYROBP-SYK signaling axis, which is well-established in the literature. TREM2 is known to signal via its adaptor protein TYROBP/DAP12 which then activates SYK kinase.

  2. Appropriate GO terms are used for molecular functions, cellular locations, and biological processes.

  3. The model includes proper evidence codes and literature references for each assertion. Most activities and relationships are supported by direct assay evidence (ECO:0000314).

  4. The addition of APOA1 as an activator of TREM2 is supported by the cited literature (PMID:27477018), which describes TREM2 binding to apolipoproteins including APOA1.

  5. The model correctly indicates the cellular locations of each protein (extracellular space for APOA1, plasma membrane for TREM2 and TYROBP, and cytoplasm for SYK).

Issues and Recommendations

  1. Biological Process Consistency: While APOA1 and TREM2 are annotated to "cellular response to lipoprotein particle stimulus" (GO:0071402), TYROBP and SYK are annotated to "cellular response to amyloid-beta" (GO:1904646). This creates an inconsistency in the biological process representation. Since this appears to be modeling APOA1-induced TREM2 signaling (not amyloid-beta), I would recommend consistently using GO:0071402 across all molecules in the pathway.

  2. Missing Mechanistic Details: The model doesn't capture the phosphorylation events that are critical for this signaling cascade. According to UniProt data, TYROBP contains ITAM domains that get phosphorylated and then recruit SYK via its SH2 domains. These mechanistic details would enhance the model.

  3. Evidence Codes: For SYK, the evidence code is "sequence similarity evidence used in manual assertion" (ECO:0000250) with "UniProtKB:P48025" in the with_objects field, indicating that this is inferred from sequence similarity to mouse. Given the importance of SYK in human myeloid cells, stronger experimental evidence specific to human SYK would strengthen the model.

  4. Missing Context: The biological context in which this pathway operates (e.g., microglia, monocytes, macrophages) is not explicitly captured in the model. TREM2 is particularly important in microglia in the brain, but this contextual information is missing.

  5. Relationship to Alzheimer's Disease: Given that TREM2 variants are risk factors for Alzheimer's disease and APOA1 is involved in lipid metabolism, the model could potentially benefit from linking to Alzheimer's disease-related processes.

Suggested Improvements

  1. Consistent Biological Process: Annotate all activities to the same biological process, either "cellular response to lipoprotein particle stimulus" or use a more specific term that appropriately captures the pathway.

  2. Add Phosphorylation Details: Include the phosphorylation of TYROBP's ITAM domain as a key regulatory step in the activation of SYK.

  3. Stronger Evidence for SYK: Replace the sequence similarity evidence for SYK with direct experimental evidence from human cells if available.

  4. Add Cell Type Context: Include annotation to indicate the cell type(s) in which this pathway operates, particularly microglia if that's the intended context.

  5. Consider Expanding the Model: The model could be expanded to include downstream targets of SYK, such as PLCĪ³2, PI3K, or other signaling molecules that TREM2 activation ultimately influences.

  6. Link to Disease Relevance: Consider adding annotations or notes about the relevance of this pathway to Alzheimer's disease, given the genetic association of TREM2 variants with AD risk.

Conclusion

The GO-CAM model 6606056e00001462 is a well-constructed representation of APOA1-activated TREM2 signaling through TYROBP and SYK. The model adheres to most GO-CAM best practices and is supported by appropriate literature evidence. With a few refinements to improve consistency in biological process annotation and add mechanistic details, the model would provide an even more accurate and informative representation of this signaling pathway.